Brokerages Set ICON Public Limited (NASDAQ:ICLR) Target Price at $287.00

Shares of ICON Public Limited (NASDAQ:ICLR) have been assigned an average recommendation of “Moderate Buy” from the fifteen analysts that are presently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $287.00.

Several analysts have weighed in on the company. TD Cowen dropped their price objective on ICON Public from $369.00 to $285.00 and set a “buy” rating for the company in a report on Friday, October 25th. Leerink Partners reaffirmed an “outperform” rating and set a $255.00 price objective (down from $270.00) on shares of ICON Public in a research note on Tuesday, November 19th. JPMorgan Chase & Co. cut their target price on ICON Public from $375.00 to $280.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. Evercore ISI lowered their price target on ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, Truist Financial reissued a “buy” rating and set a $284.00 price objective (down previously from $295.00) on shares of ICON Public in a research note on Wednesday, December 18th.

Institutional Investors Weigh In On ICON Public

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Foyston Gordon & Payne Inc acquired a new position in ICON Public during the 3rd quarter worth approximately $11,672,000. Icon Wealth Advisors LLC lifted its position in shares of ICON Public by 861.1% in the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after purchasing an additional 11,840 shares in the last quarter. Entropy Technologies LP boosted its holdings in ICON Public by 472.2% during the fourth quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company’s stock worth $1,295,000 after purchasing an additional 5,095 shares during the last quarter. Sara Bay Financial bought a new position in ICON Public in the third quarter valued at $1,143,000. Finally, Tributary Capital Management LLC increased its stake in ICON Public by 116.1% in the 4th quarter. Tributary Capital Management LLC now owns 3,950 shares of the medical research company’s stock valued at $828,000 after buying an additional 2,122 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Stock Performance

NASDAQ:ICLR opened at $197.92 on Monday. The stock has a market capitalization of $16.33 billion, a P/E ratio of 22.06, a price-to-earnings-growth ratio of 1.52 and a beta of 1.20. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. ICON Public has a 1 year low of $183.38 and a 1 year high of $347.72. The firm has a 50 day moving average of $209.86 and a 200-day moving average of $260.96.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.